{"id":"W4322769237","doi":"10.1158/1538-7445.sabcs22-pd4-03","title":"Abstract PD4-03: PD4-03 Pelareorep primes the tumor for checkpoint inhibition therapy by activating the interferon-gamma signaling pathway and tumor inflammation signature in early breast cancer patients - results of the AWARE-1 trial","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; Immune checkpoint; Breast cancer; Tumor microenvironment; Atezolizumab; Oncology; Letrozole; Cancer; Internal medicine; Immune system; Immunotherapy; Oncolytic virus; Cancer research; Immunology; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008620441,0.0004647574,0.0008902043,0.0001514816,0.0002381817,0.0008602263,0.0003489931,0.0005497789,0.001951876],"category_scores_gemma":[0.0003941065,0.0001993421,0.0007226828,0.0001753796,0.0003331301,0.0004329698,0.0002574538,0.002065019,0.0003446029],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003788661,"about_ca_system_score_gemma":0.0005056727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002813758,"about_ca_topic_score_gemma":0.0006347958,"domain_scores_codex":[0.9997239,0.0001080175,0.00001893766,0.00005711114,0.0000449991,0.00004696818],"domain_scores_gemma":[0.9997243,0.00005176923,0.0000538511,0.00003931787,0.00002367006,0.0001070012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7382824,0.028187,0.01450949,0.0005682008,0.001629759,0.0001427282,0.0001243471,0.002364468,0.09959809,0.0004146727,0.005622872,0.108556],"study_design_scores_gemma":[0.3410495,0.5464519,0.05997065,0.00009237257,0.002135966,0.0004523154,0.00017418,0.002640981,0.03600644,0.0008233793,0.01013423,0.0000680403],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995158,0.001346404,0.0002649946,0.0002434247,0.00007062569,0.0004347861,0.0009120675,0.00002724572,0.001542403],"genre_scores_gemma":[0.9925769,0.0008146109,0.0006835011,0.0005799494,0.0001174888,0.0007842218,0.002123416,0.00001413484,0.002305838],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001951876,"threshold_uncertainty_score":0.006529689,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03060723737950095,"score_gpt":0.3385175794345633,"score_spread":0.3079103420550624,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}